Efficacy and safety of infliximab and adalimumab in Crohn's disease: a single centre study
Author:
Affiliation:
1. Unità di Gastroenterologia; Dipartimento di Medicina Interna; Università di Roma ‘Tor Vergata’; Rome; Italy
2. Centro Interdipartimentale di Biostatistica e Bioinformatica; Università di Roma ‘Tor Vergata’; Rome; Italy
Publisher
Wiley
Subject
Pharmacology (medical),Gastroenterology,Hepatology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2036.2012.05100.x/fullpdf
Reference37 articles.
1. Inflammatory Bowel disease;Kaser;Annu Rev Immunol,2010
2. Tumour necrosis factor and Crohn's disease;Van Deventer;Gut,1997
3. Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease;Breese;Gastroenterology,1994
4. Tumour necrosis factor α and interleukin 1β in relapse of Crohn's disease;Schreiber;Lancet,1999
5. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group;Targan;N Engl J Med,1997
Cited by 56 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Prediction of early remission after infliximab in Crohn’s disease using baseline microbiome and metabolomics;Journal of Pharmaceutical and Biomedical Analysis;2024-12
2. Factors Predicting Loss of Remission in Crohn’s Disease Patients in Endoscopic Remission in the Real World;Journal of Clinical Gastroenterology;2024-05-22
3. CT-based pancreatic radiomics predicts secondary loss of response to infliximab in biologically naïve patients with Crohn’s disease;Insights into Imaging;2024-03-13
4. Topical issues of therapy for patients with ulcerative colitis;Meditsinskiy sovet = Medical Council;2024-01-19
5. Taraxacum coreanum Nakai extract attenuates lipopolysaccharide-induced inflammatory responses and intestinal barrier dysfunction in Caco-2 cells;Journal of Ethnopharmacology;2024-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3